Biotech News

Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard

Vivos Therapeutics (VVOS)Vivos TherapeuticsCompany update

Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (Nasdaq: VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea (“OSA”) and other breathing and sleep-related health conditions, today announced receipt of a letter from the Listing Qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) on October 20, 2026 stating that the Company currently complies with Listing Rule 5550(b)(1), requiring the Company to maintain stockholders’ equity of at least $2.5 million.

Related news

Vivos Therapeutics

Sleep-Related Breathing Disorder Platform Vivos Therapeutics is a medical technology and healthcare services company focused on obstructive sleep apnea and related breathing disorders. Its approach combines proprietary oral appliances with diagnostic and clinical services intended to address the anatomical contributors to impaired...

Recent company news

Stock data

Close
0.06 USD
Market cap
9.42M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States